ClinicalTrials.gg
CompletedNCT03119181ADEPTUpdated Jan 18, 2020Results posted

Study to Compare Active Tymbion Iontophoresis to Sham Tymbion Iontophoresis for Anesthesia of the Tympanic Membrane

A Phase 2 interventional study of Tymbion Lidocaine/epinephrine solution and Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution in Healthy Volunteer, sponsored by Tusker Medical. Completed at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by Tusker Medical (part of Smith & Nephew, Inc.) · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

A prospective, multicenter study to determine if active Tymbion iontophoresis is superior to sham Tymbion iontophoresis in providing anesthesia to the tympanic membrane (TM). The study will use the Tula iontophoresis systems for healthy adult volunteers in an office setting, called Group A of Protocol CPR007003.

The protocol CPR007003 also includes a Group B study described in a separate Registration (NCT03197558).

Read the detailed description

The objective of the study is to determine if active Tymbion iontophoresis is superior to sham Tymbion iontophoresis in providing anesthesia to the tympanic membrane. In addition, safety will be evaluated by review of the occurrence of adverse events.

The iontophoresis system (IPS) will be used to facilitate anesthetic delivery to the tympanic membrane (TM). The lidocaine-based solution used for local anesthesia of the TM is Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine).

Group A will consist of 40 evaluable healthy adult subjects randomized (1:1) to receive unilateral treatment (1 ear) with either active Tymbion iontophoresis or sham Tymbion iontophoresis. The sham iontophoresis procedure will be identical to the active Tymbion iontophoresis, with the exception that the iontophoresis current will not be activated (ie, the same drug solution will be applied to ears in both arms). After the completion of the iontophoresis procedure, the tympanic membrane will be tapped with a dull otologic probe to test the level of anesthesia. The subject will rate the level of pain using the Visual Analogue Scale (VAS) immediately after the tap. Investigators and subjects will be blinded to treatment assignment.

Safety assessments will be done post procedure and at follow as applicable.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Tusker Medical is the lead sponsor of 3 studies on the registry; none are open to participants now.

First submitted before Tusker Medical became part of Smith & Nephew, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Key Inclusion/Exclusion Criteria

Inclusion criteria

Inclusion Criteria Group A:

  1. Healthy adults, 18-50 years old
  2. Subject is able and willing to comply with the protocol and attend all study visits
  3. Subject is able and willing to provide
  4. Subjects with air conduction hearing thresholds of 25 dB HL or better at standard frequencies up to 2000 Hz, and 45 dB or better at 4000 Hz.
  5. Subject is able to read and understand English

Exclusion criteria

Exclusion Criteria Group A:

  1. Pregnant or lactating females.
  2. Prior ear iontophoresis procedure
  3. Subjects with conductive hearing loss.
  4. Subjects with history of sensitivity or allergic reaction to lidocaine HCl, tetracaine, epinephrine, or any to local anesthetics of the amide type, or any component of the anesthetic drug formulation.
  5. Familial history of insensitivity to lidocaine or other local anesthetics of the amide type.
  6. Significantly atrophic, retracted, bimeric, monomeric or atelectatic tympanic membrane.
  7. Perforated tympanic membrane.
  8. Subjects with known history of ear surgery or TM condition that has the potential to affect the sensitivity of the TM
  9. Otitis externa.
  10. Damaged/denuded skin in the auditory canal.
  11. Subjects with electrically sensitive support systems
  12. Cerumen impaction resulting in a significant amount of cleaning required to visualize the tympanic membrane.
  13. Evidence of Otitis Media at day of procedure, or within the past three (3) months prior to procedure.
  14. Other conditions that would preclude performing the study procedure including ear plug incompatibility.
  15. Health conditions that, in the opinion of the investigator, would present undue risk to the subject, based on device/anesthetic drug product label warnings and precautions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Active Tymbion Iontophoresis

    Unilateral treatment with active iontophoresis of Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine) using the Tusker Medical Tula Iontophoresis System.

    Combination Product: Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution

  • Sham comparator
    Sham Tymbion Iontophoresis

    The sham iontophoresis procedure will be identical to the active Tymbion iontophoresis in that Tymbion (2% lidocaine/ 1:100,000 epinephrine solution) will be placed in the external ear canal, however the iontophoresis current delivery (which facilitates penetration of drug into the tympanic membrane tissue) will not be activated.

    Drug: Tymbion Lidocaine/epinephrine solution

Interventions

  • DrugTymbion Lidocaine/epinephrine solution

    The external ear canal will be filled with Tymbion drug solution

    Also known as: 2% lidocaine HCl/ 1:100,000 epinephrine, Tymbion

  • Combination productDevice: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution

    The external ear canal will be filled with Tymbion drug solution. The Iontophoresis System (IPS) will be used to deliver current to the Tymbion solution to facilitate drug penetration into the tympanic membrane (TM) tissue to anesthetize (numb) the TM

    Also known as: Tula Iontophoresis System, 2% lidocaine HCl/1:100,000 epinephrine, Tymbion

06

What researchers measure

Primary outcomes

  1. Subject-reported Visual Analog Scale (VAS) Pain Score Following Tympanic Membrane Tap for Subjects Treated With Active Tymbion Iontophoresis Compared to VAS Score for Subjects Treated With Sham Tymbion Iontophoresis.

    The VAS consists of a 100 millimeter (mm) line with a statement at each end representing the extreme limits of pain intensity (where 0 represents "No pain" and 100 represents "The worst imaginable pain"). The subject reports their pain intensity by making a mark along the line and the line is measured to convert the subject response to numeric score (0-100 in millimeters). The data will be summarized as the difference in mean VAS scores between the two treatment groups (active Tymbion iontophoresis compared to sham Tymbion iontophoresis).

    Time frame: Day 0

07

Results

Posted Jan 6, 2020

Participant flow

Participant flow — Overall Study
MilestoneActive Tymbion IontophoresisSham Tymbion Iontophoresis
Started1921
Completed1921
Not completed00

Outcome measures

PrimarySubject-reported Visual Analog Scale (VAS) Pain Score Following Tympanic Membrane Tap for Subjects Treated With Active Tymbion Iontophoresis Compared to VAS Score for Subjects Treated With Sham Tymbion Iontophoresis.

The VAS consists of a 100 millimeter (mm) line with a statement at each end representing the extreme limits of pain intensity (where 0 represents "No pain" and 100 represents "The worst imaginable pain"). The subject reports their pain intensity by making a mark along the line and the line is measured to convert the subject response to numeric score (0-100 in millimeters). The data will be summarized as the difference in mean VAS scores between the two treatment groups (active Tymbion iontophoresis compared to sham Tymbion iontophoresis).

Time frame:
Day 0
Reported as:
Mean · millimeters
Subject-reported Visual Analog Scale (VAS) Pain Score Following Tympanic Membrane Tap for Subjects Treated With Active Tymbion Iontophoresis Compared to VAS Score for Subjects Treated With Sham Tymbion Iontophoresis.
millimetersActive Tymbion IontophoresisSham Tymbion Iontophoresis
Subject-reported Visual Analog Scale (VAS) Pain Score Following Tympanic Membrane Tap for Subjects Treated With Active Tymbion Iontophoresis Compared to VAS Score for Subjects Treated With Sham Tymbion Iontophoresis.4.2 ± 13.118.3 ± 24.1
Statistical analysis
  • Active Tymbion Iontophoresis vs Sham Tymbion Iontophoresis · one-sided permutation test · p = 0.0097

Adverse events

Collected over Procedure through 3 days post-procedure. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Tymbion Iontophoresis0/19 (0%)0/19 (0%)1/19 (5.3%)
Sham Tymbion Iontophoresis0/21 (0%)0/21 (0%)0/21 (0%)
Most frequent other events
Most frequent other events
EventActive Tymbion IontophoresisSham Tymbion Iontophoresis
SyncopeNervous system disorders1/190/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Active Tymbion IontophoresisSham Tymbion IontophoresisTotal
Mean29.9 ± 7.731.9 ± 7.430.9 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Active Tymbion IontophoresisSham Tymbion IontophoresisTotal
Female71017
Male121123
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active Tymbion IontophoresisSham Tymbion IontophoresisTotal
Hispanic or Latino459
Not Hispanic or Latino151631
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active Tymbion IontophoresisSham Tymbion IontophoresisTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American202
White141731
More than one race000
Unknown or Not Reported347
Region of Enrollment
Region of Enrollment(participants)Active Tymbion IontophoresisSham Tymbion IontophoresisTotal
United States192140
08

Study locations

2 sites
  • Camino ENT
    San Jose, California 95138, United States
  • Specialty Physician Associates
    Bethlehem, Pennsylvania 18017, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in May 2017, 0 months.

Results were first posted in Jan 2020, 2 years 7 months after primary completion. A results delay was requested in May 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2017
First posted
Apr 18, 2017
StartActual
Apr 27, 2017
Primary completionActual
May 11, 2017
CompletionActual
May 11, 2017
Results delay requested
May 28, 2019
Results first posted
Jan 6, 2020
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03119181
Lead sponsor
Tusker Medical
Responsible party
Sponsor
First posted
Apr 18, 2017
Start date
Apr 27, 2017
Primary completion
May 11, 2017
Completion
May 11, 2017
Results posted
Jan 6, 2020
Last update
Jan 18, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion